Ipsen: Information Relating to the Holding of the Combined Shareholders’ Meeting of 24 May 2022
03 Mai 2022 - 7:30AM
Business Wire
FORMALITIES FOR MAKING AVAILABLE AND
CONSULTING PREPARATORY DOCUMENTS TO THE MEETING
Regulatory News:
The Shareholders of the Company are invited to participate in
the Combined Shareholders’ Meeting of Ipsen (Euronext: IPN; ADR:
IPSEY) to be held on Tuesday, 24 May 2022 at 3:00 p.m. (Paris time)
at the Salons de l'Hôtel des Arts et Métiers, 9 bis avenue d'Iéna,
75116 Paris.
The preliminary notice of the Meeting (“avis de réunion”) was
published in the Bulletin des Annonces Légales Obligatoires (BALO)
of 15 April 2022 and the notice of Meeting (“avis de convocation”)
will be published in the BALO on 6 May 2022. These documents, as
well as the Convening notice (including the agenda, the draft
resolutions and the conditions regarding attendance and vote), are
also available on Ipsen’s website at the following address:
www.ipsen.com, under the Investors / Shareholders’ Meetings
section. Documents and information relating to this Meeting are
made available to shareholders under the legal and regulatory
conditions in force.
The Shareholders will be asked to approve in particular the
following resolutions:
- The payment of a dividend of €1.20 per share for the financial
year 2021, the ex-date being set on 31 May 2022 and the dividend
payment on 2 June 2022;
- The renewal of the terms of office of Highrock S.àr.l., Mr.
Paul SEKHRI and Mr. Piet WIGERINCK as Directors for a term of 4
years, as well as the ratification of the temporary appointment of
Mrs. Karen WITTS as a Director, maintaining the independence
Directors’ rate within the Board of Directors at a third in
accordance with the Afep-Medef Code and each gender’s proportion at
more than 40% in accordance with the law (the Director representing
the employees being not taken into account in these rates).
In accordance with applicable regulatory provisions:
- Registered shareholders may, up to the fifth day (inclusive)
before the Meeting, request from the Company to send these
documents, where appropriate at his/her express request by
electronic means. For holders of bearer shares, the exercise of
this right is subject to the presentation of a shareholding
certificate (attestation de participation) in the bearer securities
accounts managed by the authorized intermediary.
- Any shareholder may consult these documents at the Company’s
headquarters.
In the context of the Covid-19 pandemic, the Company may have to
modify the procedures for holding and/or participating in the
Shareholders' Meeting of 24 May 2022. Shareholders are invited to
regularly consult the page dedicated to the 2022 Shareholders'
Meeting on the Company's website (www.ipsen.com, section Investors
/ Shareholders' Meeting) in order to have access to all the updated
information concerning the Shareholders' Meeting and the final
terms of participation.
Ipsen
Ipsen is a global, mid-sized biopharmaceutical company focused
on transformative medicines in Oncology, Rare Disease and
Neuroscience. With Specialty Care sales of €2.6bn in FY 2021, Ipsen
sells medicines in over 100 countries. Alongside its
external-innovation strategy, the Company’s research and
development efforts are focused on its innovative and
differentiated technological platforms located in the heart of
leading biotechnological and life-science hubs: Paris-Saclay,
France; Oxford, U.K.; Cambridge, U.S.; Shanghai, China. Ipsen,
excluding its Consumer HealthCare business, has around 4,500
colleagues worldwide and is listed in Paris (Euronext: IPN) and in
the U.S. through a Sponsored Level I American Depositary Receipt
program (ADR: IPSEY). For more information, visit ipsen.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220502005669/en/
Ipsen
Ipsen (EU:IPN)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Ipsen (EU:IPN)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024